Education
About Us
Working with TipRanks
Follow Us
MDxHealth (MDXH)
NASDAQ:MDXH
MDXH Stock Chart & Stats
$3.32
-$0.10(-4.55%)
At close: 4:00 PM EST
$3.32
-$0.10(-4.55%)
Day’s Range― - ―
52-Week Range$1.35 - $5.33
Previous CloseN/A
Volume27.23K
Average Volume (3M)165.62K
Market Cap
$168.79M
Enterprise Value$286.05M
Total Cash (Recent Filing)$32.81M
Total Debt (Recent Filing)$84.01M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Mar 04, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding49,497,334
10 Day Avg. Volume119,056
30 Day Avg. Volume165,622
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)7.77
Price to Sales (P/S)1.28
P/FCF Ratio-5.57
Enterprise Value/Market Cap1.69
Enterprise Value/Revenue5.38
Enterprise Value/Gross Profit8.14
Enterprise Value/Ebitda408.65
Forecast
1Y Price Target
$7.67Price Target Upside131.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.58
Revenue Forecast (FY)$108.87M
Bulls Say, Bears Say
Bulls Say
Earnings And Price TargetMDXH raised its price target to $7, reflecting confidence in future performance and growth prospects.
Revenue GrowthMDXH sees a path to achieve revenue growth of 30% in 2026, boosted by its recent acquisition of ExoDx.
Stock ValuationShares of MDXH trade at just 1.4x the initial 2027 revenue estimate, below small cap peers at 2x, indicating potential for multiple expansion.
Bears Say
MDxHealth News
MDXH FAQ
What was MDxHealth’s price range in the past 12 months?
MDxHealth lowest stock price was $1.35 and its highest was $5.33 in the past 12 months.
What is MDxHealth’s market cap?
MDxHealth’s market cap is $168.79M.
When is MDxHealth’s upcoming earnings report date?
MDxHealth’s upcoming earnings report date is Mar 04, 2026 which is in 80 days.
How were MDxHealth’s earnings last quarter?
MDxHealth released its earnings results on Nov 12, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.107 by -$0.053.
Is MDxHealth overvalued?
According to Wall Street analysts MDxHealth’s price is currently Undervalued.
Does MDxHealth pay dividends?
MDxHealth does not currently pay dividends.
What is MDxHealth’s EPS estimate?
MDxHealth’s EPS estimate is -0.13.
How many shares outstanding does MDxHealth have?
MDxHealth has 49,497,334 shares outstanding.
What happened to MDxHealth’s price movement after its last earnings report?
MDxHealth reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.107. Following the earnings report the stock price went down -3.641%.
Which hedge fund is a major shareholder of MDxHealth?
Currently, no hedge funds are holding shares in MDXH
MDxHealth Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (131.02% Upside)
$7.67 (131.02% Upside)
Blogger Sentiment
Bullish
MDXH Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.7%
Last 30 Days ▼ 14.7%
Last 30 Days ▼ 14.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.67%
12-Months-Change
Fundamentals
Return on Equity
-720.01%
Trailing 12-Months
Asset Growth
-1.99%
Trailing 12-Months
Company Description
MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MDXH Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted robust revenue and volume growth, improved gross margins, and a successful acquisition of ExoDx. However, these positives were tempered by the discontinuation of the germline offering and ongoing net and operating losses. Overall, the sentiment reflects a company making strategic adjustments for future growth while managing current financial challenges.View all MDXH earnings summariesMDXH Stock 12 Month Forecast
Average Price Target
$7.67
▲(131.02% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.09% Mutual Funds
43.48% Other Institutional Investors
56.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---